

REMARKS

Claims 58, 68, 74, 75, 78, 79 and 80 are currently amended. Claims 81-87 have been added. No new matter is added. Consideration is urged in light of the amendments above are within the guidelines of within the guidelines of 37 CFR 1.312.

I. Interview Summary

On September 23, 2010 Examiner Gebreyesus and Michael Krenicky, attorney for the applicant, had a telephonic interview to discuss claims 58, 61-68 and 71-77. New claims 78-80 were proposed.

It was agreed that claims 58, 68, 61 and 73 would be amended as set out in the Interview summary included in the Notice of Allowance mailed 10/28/2010. Claims 78-80 were newly added and it was agreed they were in condition for allowance. Claims 62, 66, 72 and 76 were cancelled.

No prior art was discussed.

No demonstrations were made.

No other issues were discussed at this time.

II. ARGUMENTS:

Claims 58, 68, 74, 75, 78, 79 and 80 are currently amended within the guidelines of 37 CFR 1.312.

Claims 81 to 87 are newly added within the guidelines of 37 CFR 1.312. Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc. *i.e.*, Deposit Account No. 50-1701.

Consideration is urged.

III. Conclusion

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc. *i.e.*, Deposit Account No. 50-1701.

Respectfully submitted,

Date: January 28, 2011

/Michael W. Krenicky Reg # 45411/
Michael W. Krenicky, Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097